Allergy Therapeutics PLC Overview
Pro stress-test →Allergy Therapeutics is a UK-based biotechnology company focused on developing and commercializing immunotherapies for allergic disorders. The company operates across nine European countries with a portfolio of injectable and sublingual allergen-specific immunotherapies, targeting both established markets (Germany, Austria, Netherlands, Switzerland, Spain, Italy) and emerging opportunities.
Strategic Profile
Pro stress-test →The company combines commercial products like Pollinex Quattro and Oralvac with a promising R&D pipeline including Grass MATA MPL and VLP Peanut vaccine. Strategic positioning emphasizes aluminum-free immunotherapy technology with curative potential, supported by centralized UK manufacturing and R&D capabilities. Recent financing from Hayfin (£40m facility) and pursuit of Hong Kong listing indicate growth ambitions and geographic expansion strategy.
Competitive Landscape
Pro stress-test →Allergy Therapeutics competes in the specialized immunotherapy space against larger pharma entities like Stallergenes Greer and smaller regional players. The company's competitive advantage lies in aluminum-free formulations and established European distribution networks, but faces competition from emerging oral immunotherapy platforms and increasing interest from major pharma in allergy vaccines.
Industry Context
Allergy Therapeutics PLC operates in Specialty Pharmaceuticals / Biotechnology - Immunotherapy.
Key facts
Founded: 1998 · Headquarters: Worthing, UK · Employees: 584 · Revenue: £71.2m · Market cap: £706m (~$900m USD equiv.)